Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Public ClinicalTrials.gov record NCT05270668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
Study identification
- NCT ID
- NCT05270668
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Interventions
- Companion diagnostic ( CDx) Diagnostic Test
- Placebo Drug
- Tulisokibart Drug
Diagnostic Test · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2022
- Primary completion
- Apr 15, 2026
- Completion
- Jul 30, 2029
- Last update posted
- May 17, 2026
2022 – 2029
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Scottsdale ( Site 4014) | Phoenix | Arizona | 85054 | — |
| Pacific Arthritis Care Center ( Site 4008) | Los Angeles | California | 90045 | — |
| Cedars Sinai Medical Center ( Site 4010) | Los Angeles | California | 90048 | — |
| UCLA School of Medicine ( Site 4006) | Los Angeles | California | 90095-1670 | — |
| Stanford Health Care ( Site 4009) | Palo Alto | California | 94304 | — |
| National Jewish Health Medical Center ( Site 4015) | Denver | Colorado | 80206 | — |
| Yale University ( Site 4017) | New Haven | Connecticut | 06519 | — |
| MedStar Georgetown University Hospital ( Site 4005) | Washington D.C. | District of Columbia | 20007 | — |
| Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018) | Baltimore | Maryland | 21224 | — |
| Massachusetts General Hospital ( Site 4003) | Boston | Massachusetts | 02114 | — |
| Boston University School of Medicine ( Site 4021) | Boston | Massachusetts | 02118 | — |
| University of Michigan Hospital ( Site 4001) | Ann Arbor | Michigan | 48109 | — |
| Rutgers Robert Wood Johnson Medical School ( Site 4013) | New Brunswick | New Jersey | 08901 | — |
| Hospital For Special Surgery ( Site 4020) | New York | New York | 10021 | — |
| Cleveland Clinic Foundation ( Site 4019) | Cleveland | Ohio | 44195 | — |
| University of Toledo Medical Center ( Site 4002) | Toledo | Ohio | 43614 | — |
| University of Pittsburgh Medical Center ( Site 4016) | Pittsburgh | Pennsylvania | 15213 | — |
| Medical University of South Carolina - PPDS ( Site 4004) | Charleston | South Carolina | 29425 | — |
| UT Physicians Rheumatology ( Site 4007) | Houston | Texas | 77030 | — |
| Froedtert and Medical College of Wisconsin ( Site 4012) | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05270668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05270668 live on ClinicalTrials.gov.